Newswire (Published: Tuesday, January 17, 2017, Received: Thursday, January 12, 2017, 3:40:35 PM CST)

Word Count: 365

Studies from Cleveland Clinic Add New Findings in the Area of Prostate Cancer (Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Cleveland, Ohio, by NewsRx correspondents, research stated, "Treatment choices for men with indolent prostate cancer include active surveillance or definitive local therapy. Overtreatment of these patients is an important current problem."

Our news editors obtained a quote from the research from Cleveland Clinic, "Treatment decisions are often made jointly by the clinician and the patient, partly based on the tumour's Gleason score. To reduce the burden of overtreatment, the clinical significance of Gleason score 3 + 3=6 prostate cancer has been questioned and some have advocated that Gleason pattern 3 should be stripped of its cancer status. However, removing the cancer descriptor would have far-reaching clinical consequences that might result in poor patient outcomes, as the evidence of a lack of malignancy is inconclusive in several areas. For example, molecular data suggest that the genomic instability underlying tumor progression precedes histologically visible changes and the absolute risk of metastasis or mortality from Gleason score 6 prostate cancer is not zero."

According to the news editors, the research concluded: "Extreme caution is required when weighing a decision to reclassify Gleason pattern 3 disease as a non-cancer."

For more information on this research see: Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. Nature Reviews Urology, 2016;():. (Nature Publishing Group - www.nature.com/; Nature Reviews Urology - www.nature.com/nrurol/)

The news editors report that additional information may be obtained by contacting C.A. Reichard, Cleveland Clinic, Glickman Urological &Kidney Institute, 9500 Euclid Avenue, Q10-1, Cleveland, Ohio 44195, United States (see also Oncology - Prostate Cancer).

Keywords for this news article include: Ohio, Genetics, Oncology, Cleveland, Epidemiology, United States, Article Review, Prostate Cancer, Prostatic Neoplasms, Risk and Prevention, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
North America
United States
Americas
Ohio
Cleveland

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Genetics
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Urology
      Treatments and Therapies